FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Seen in 1 in 3 million births, the malformation was detected at the antenatal stage during the mother's pregnancy
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
A treatment to prevent extreme symptoms and cut hospitalisation
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
All India Institute of Ayurveda hosts ministers and showcase their achievements
The transaction is expected to close in the Q4FY22
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Subscribe To Our Newsletter & Stay Updated
